MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 47 | 0.0 |
Humans | 113 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 2 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Review Literature | 2 | 1.0 |
Animals | 13 | 0.0 |
Base Sequence | 19 | 0.0 |
Cell Line, Tumor | 11 | 0.0 |
Melanocytes/cytology/metabolism | 2 | 20.0 |
Mice | 8 | 0.0 |
Phosphorylation | 4 | 0.0 |
Protein Binding | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 62 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Cell Division | 6 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
DNA Mutational Analysis | 23 | 0.0 |
Enzyme Activation | 3 | 0.0 |
MAP Kinase Signaling System | 6 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 6 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Proto-Oncogene Proteins B-raf | 63 | 90.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Adult | 26 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Codon | 5 | 1.0 |
Colorectal Neoplasms/*genetics | 5 | 2.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 2 | 2.0 |
Cytoskeletal Proteins/genetics | 2 | 3.0 |
*DNA Mutational Analysis | 6 | 3.0 |
Exons | 16 | 0.0 |
Genes, ras/genetics | 3 | 2.0 |
Germ-Line Mutation | 3 | 0.0 |
Loss of Heterozygosity | 3 | 0.0 |
Male | 38 | 0.0 |
Middle Aged | 32 | 0.0 |
Mutation | 22 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Genes, ras/*genetics | 16 | 16.0 |
Microsatellite Repeats | 9 | 0.0 |
Polymerase Chain Reaction | 24 | 0.0 |
Proto-Oncogene Proteins B-raf/*genetics | 12 | 100.0 |
Retrospective Studies | 4 | 0.0 |
United States | 2 | 0.0 |
Disease Progression | 5 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Signal Transduction | 5 | 0.0 |
Carcinoma, Papillary/*genetics | 7 | 22.0 |
Child | 7 | 0.0 |
*Mutation | 29 | 0.0 |
Oncogene Proteins/*genetics | 18 | 12.0 |
Proto-Oncogene Proteins c-raf/*genetics | 35 | 92.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
Comparative Study | 10 | 0.0 |
DNA Primers | 6 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Proto-Oncogene Proteins c-raf/*biosynthesis/*genetics | 2 | 100.0 |
Aged | 27 | 0.0 |
Aged, 80 and over | 16 | 0.0 |
*DNA Methylation | 3 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
MAP Kinase Signaling System/physiology | 2 | 2.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Proto-Oncogene Proteins c-raf/*genetics/metabolism | 4 | 80.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Transfection | 2 | 0.0 |
Adolescent | 7 | 0.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
*Genes, ras | 7 | 3.0 |
Immunohistochemistry | 6 | 0.0 |
Melanoma/*genetics/pathology | 5 | 18.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 10 | 0.0 |
Skin Neoplasms/*genetics/pathology | 5 | 9.0 |
Alleles | 4 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Models, Biological | 3 | 0.0 |
Neoplasm Staging | 7 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
DNA Mutational Analysis/methods | 2 | 0.0 |
Mutation, Missense | 4 | 0.0 |
Thyroid Neoplasms/*genetics/pathology | 2 | 6.0 |
Base Pair Mismatch | 2 | 1.0 |
Proto-Oncogene Proteins/*genetics | 8 | 0.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
*Point Mutation | 5 | 0.0 |
Prevalence | 2 | 0.0 |
Genes, ras | 3 | 1.0 |
Neoplasms/*genetics | 3 | 1.0 |
Proto-Oncogene Proteins/genetics | 4 | 0.0 |
Proto-Oncogene Proteins c-raf/genetics | 3 | 60.0 |
Disease-Free Survival | 2 | 0.0 |
Melanoma/*enzymology/genetics/pathology | 2 | 66.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Point Mutation | 4 | 0.0 |
Exons/genetics | 5 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Adenine | 2 | 3.0 |
DNA/metabolism | 2 | 0.0 |
Head and Neck Neoplasms/*genetics | 2 | 2.0 |
Models, Genetic | 2 | 0.0 |
Skin Neoplasms/*genetics | 5 | 4.0 |
Cystadenoma, Serous/*genetics/pathology | 3 | 100.0 |
Ovarian Neoplasms/*genetics/pathology | 5 | 6.0 |
Chernobyl Nuclear Accident | 2 | 100.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
*MAP Kinase Signaling System | 2 | 1.0 |
Recombination, Genetic/genetics | 2 | 2.0 |
Thyroid Neoplasms/*genetics/*metabolism/pathology | 2 | 100.0 |
Time Factors | 3 | 0.0 |
Oncogenes/genetics | 2 | 2.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Gene Amplification | 2 | 0.0 |
Molecular Biology | 2 | 0.0 |
Oncogene Proteins, Fusion/genetics | 2 | 2.0 |
Base Pair Mismatch/genetics | 2 | 4.0 |
Biopsy, Fine-Needle | 2 | 10.0 |
*Chromosome Mapping | 2 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 4 | 0.0 |
Melanoma/*genetics | 7 | 4.0 |
Amino Acid Substitution | 2 | 0.0 |
ras Proteins/genetics | 3 | 21.0 |
RNA, Small Interfering/metabolism | 2 | 1.0 |
Signal Transduction/physiology | 3 | 0.0 |
Mutation/*genetics | 9 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Sunlight/adverse effects | 2 | 10.0 |
Melanoma/*genetics/secondary | 2 | 14.0 |
Skin Neoplasms/genetics | 2 | 6.0 |
Melanoma/etiology/*genetics | 2 | 22.0 |
Skin Neoplasms/etiology/*genetics | 2 | 33.0 |
DNA Methylation | 2 | 0.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Phenotype | 2 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Stomach Neoplasms/*genetics | 3 | 2.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
ras Proteins/*metabolism | 2 | 1.0 |
Heterozygote | 2 | 0.0 |
Uveal Neoplasms/*genetics | 2 | 20.0 |
Thyroid Neoplasms/*genetics | 5 | 5.0 |
Base Sequence/genetics | 2 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Colorectal Neoplasms/*genetics/pathology | 3 | 3.0 |
*Genome, Human | 2 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
